Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence.
Cardiovascular disease
Glucagon-like-peptide 1 agonists
Major adverse cardiovascular event
Sodium-glucose cotransporter-2 inhibitor
Type 2 diabetes mellitus
Journal
World journal of diabetes
ISSN: 1948-9358
Titre abrégé: World J Diabetes
Pays: United States
ID NLM: 101547524
Informations de publication
Date de publication:
15 May 2019
15 May 2019
Historique:
received:
01
04
2019
revised:
13
05
2019
accepted:
13
05
2019
entrez:
30
5
2019
pubmed:
30
5
2019
medline:
30
5
2019
Statut:
ppublish
Résumé
Cardiovascular diseases (CVDs) remain the leading cause of death in the world and in most developed countries. Patients with type 2 diabetes mellitus (T2DM) suffer from both microvascular and macrovascular diseases and therefore have higher rates of morbidity and mortality compared to those without T2DM. If current trends continue, the Center for Disease Control and Prevention estimates that 1 in 3 Americans will have T2DM by year 2050. As a consequence of the controversy surrounding rosiglitazone and the increasing prevalence of diabetes and CVDs, in 2008 the Food and Drug Administration (FDA) established new expectations for the evaluation of new antidiabetic agents, advising for pre and, in some cases, post-marketing data on major cardiovascular events. As a direct consequence, there has been a paradigm shift in new antidiabetic agents that has given birth to the recently published American Diabetes Association/European Association for the Study of Diabetes consensus statement recommending sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon like peptide-1 receptor agonists (GLP-1RA) in patients with T2DM and established CVD. As a result of over a decade of randomized placebo controlled cardiovascular outcome trials, the aforementioned drugs have received FDA approval for risk reduction of cardiovascular (CV) events in patients with T2DM and established CV disease. SGLT2i have been shown to have a stronger benefit in patients with congestive heart failure and diabetic kidney disease when compared to their GLP-1RA counterparts. These benefits are not withstanding additional considerations such as cost and the multiple FDA Black Box warnings. This topic is currently an emerging research area and this mini-review paper examines the role of these two novel classes of drugs in patients with T2DM with both confirmed, and at risk for, CVD.
Identifiants
pubmed: 31139316
doi: 10.4239/wjd.v10.i5.291
pmc: PMC6522760
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
291-303Déclaration de conflit d'intérêts
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Références
Ann Intern Med. 2000 Jul 18;133(2):81-91
pubmed: 10896647
Am J Physiol Renal Physiol. 2004 Jan;286(1):F127-33
pubmed: 14506074
N Engl J Med. 2005 Dec 22;353(25):2643-53
pubmed: 16371630
N Engl J Med. 2008 Jun 12;358(24):2545-59
pubmed: 18539917
N Engl J Med. 2009 Jan 8;360(2):129-39
pubmed: 19092145
Diabetes Care. 2009 Jul;32(7):1224-30
pubmed: 19289857
Lancet. 2009 May 30;373(9678):1849-60
pubmed: 19482214
Clin J Am Soc Nephrol. 2010 Jan;5(1):133-41
pubmed: 19965550
Endocrinology. 2010 Apr;151(4):1473-86
pubmed: 20203154
N Engl J Med. 2010 Apr 29;362(17):1575-85
pubmed: 20228401
N Engl J Med. 2010 Apr 29;362(17):1563-74
pubmed: 20228404
J Clin Endocrinol Metab. 2011 Mar;96(3):853-60
pubmed: 21209033
Physiol Rev. 2011 Apr;91(2):733-94
pubmed: 21527736
JAMA. 2012 Aug 8;308(6):581-90
pubmed: 22871870
Lancet. 2013 Jan 12;381(9861):117-24
pubmed: 23141817
Diabetes Obes Metab. 2013 Aug;15(8):737-49
pubmed: 23433305
Diabetes Care. 2013 Aug;36(8):2366-71
pubmed: 23435157
BMJ. 2013 Jul 29;347:f4533
pubmed: 23900314
Ann Intern Med. 2013 Aug 20;159(4):262-74
pubmed: 24026259
Diabetes Metab Res Rev. 2014 Mar;30(3):204-21
pubmed: 24115369
Am J Hypertens. 2014 Jan;27(1):130-9
pubmed: 24263424
N Engl J Med. 2014 Feb 27;370(9):794-7
pubmed: 24571751
Drug Des Devel Ther. 2014 Sep 11;8:1335-80
pubmed: 25246775
Diabetes Care. 2015 Mar;38(3):420-8
pubmed: 25271206
Expert Opin Drug Saf. 2014 Nov;13(11):1535-44
pubmed: 25340618
Lancet. 2015 Apr 11;385(9976):1397-405
pubmed: 25579834
Diabetologia. 2015 Mar;58(3):429-42
pubmed: 25583541
Physiol Rev. 2015 Apr;95(2):513-48
pubmed: 25834231
N Engl J Med. 2015 Jul 2;373(1):11-22
pubmed: 26132939
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
J Clin Endocrinol Metab. 2016 Jan;101(1):157-66
pubmed: 26580237
N Engl J Med. 2015 Dec 3;373(23):2247-57
pubmed: 26630143
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016
pubmed: 27651331
Obes Sci Pract. 2017 Mar;3(1):3-14
pubmed: 28392927
Diabetes Metab. 2017 Apr;43 Suppl 1:2S20-2S27
pubmed: 28431667
Diabetologia. 2018 Feb;61(2):265-272
pubmed: 28501906
Diabetes Obes Metab. 2018 Jan;20(1):42-49
pubmed: 28573765
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Biomed Pharmacother. 2017 Oct;94:176-187
pubmed: 28759755
N Engl J Med. 2017 Sep 28;377(13):1228-1239
pubmed: 28910237
Cureus. 2017 Oct 5;9(10):e1751
pubmed: 29226041
Atherosclerosis. 2018 May;272:33-40
pubmed: 29547706
J Clin Med Res. 2018 Jun;10(6):466-477
pubmed: 29707088
Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617
pubmed: 29910024
N Engl J Med. 2018 Oct 18;379(16):1529-1539
pubmed: 30146931
CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):788-797
pubmed: 30270578
Diabetes Obes Metab. 2019 Mar;21(3):499-508
pubmed: 30284349
Diab Vasc Dis Res. 2019 Jan;16(1):103-107
pubmed: 30284913
Lancet. 2018 Oct 27;392(10157):1519-1529
pubmed: 30291013
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Diabetes Metab. 2019 Apr;45(2):110-121
pubmed: 30477733
Ann Pharmacother. 2019 May;53(5):510-522
pubmed: 30516068
Circulation. 2018 Nov 29;:null
pubmed: 30586745
Expert Opin Pharmacother. 2019 Apr;20(5):585-593
pubmed: 30614740
JAMA Netw Open. 2018 Nov 2;1(7):e183788
pubmed: 30646365
Diabetes Obes Metab. 2019 May;21(5):1237-1250
pubmed: 30697905
N Engl J Med. 2019 Apr 14;:null
pubmed: 30990260
J Clin Endocrinol Metab. 1986 Aug;63(2):492-8
pubmed: 3522621
Diabetes. 1983 May;32(5):387-91
pubmed: 6132846
FEBS Lett. 1995 Jan 30;358(3):219-24
pubmed: 7843404
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976